Abstract
S-18886, the active isomer of S-18204, is a thromboxane A2 receptor antagonist with a long duration of action. The compound is under development by Servier for the potential treatment of cardiovascular diseases [269611]. By 2000, a clinical trial had been carried out in patients with coronary artery disease [389458]; advanced clinical trials were ongoing in August 2001 [420310].
MeSH terms
-
Animals
-
Cardiovascular Diseases / drug therapy
-
Clinical Trials as Topic / methods
-
Clinical Trials as Topic / statistics & numerical data
-
Drug Industry / legislation & jurisprudence*
-
Drug Industry / methods
-
Humans
-
Naphthalenes
-
Propionates
-
Tetrahydronaphthalenes / chemistry
-
Tetrahydronaphthalenes / pharmacology
-
Tetrahydronaphthalenes / therapeutic use*
Substances
-
Naphthalenes
-
Propionates
-
Tetrahydronaphthalenes
-
terutroban